RBC Capital upgraded Sage Therapeutics (SAGE) to Sector Perform from Underperform with an unchanged price target of $4.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics reported another clinical setback, says H.C. Wainwright
- Sage Therapeutics reports results from Phase 2 DIMENSION Study
- Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
- Sage Therapeutics price target lowered to $9 from $11 at Morgan Stanley
- SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures
Questions or Comments about the article? Write to editor@tipranks.com